Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C

  • Major change
  • Protocol
  • Intervention

Authors

  • Tahany Awad,

    Corresponding author
    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    • Tahany Awad, Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. tahany@ctu.rh.dk.

    Search for more papers by this author
  • Kristian Thorlund,

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • Goran Hauser,

    1. Clinical Hospital Centre of Rijeka, Clinics of Internal Medicine - Gastroenterology, Rijeka, Croatia
    Search for more papers by this author
  • Mahasen Mabrouk,

    1. Faculty of Medicine, Cairo University, Endemic Medicine, Department 2, Cairo, Egypt
    Search for more papers by this author
  • Davor Stimac,

    1. Clinical Hospital Centre of Rijeka, Clinics of Internal Medicine - Gastroenterology, Rijeka, Croatia
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefits and harms of pegylated interferon alpha 2a versus pegylated interferon alpha 2b for patients with chronic hepatitis C.